Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel (NASDAQ: RIGL) published final five-year results from the Phase 2 pivotal cohort of REZLIDHIA (olutasidenib) in relapsed/refractory mIDH1 acute myeloid leukemia in Journal of Hematology & Oncology on Nov 17, 2025. Key five-year findings: CR/CRh 35% (n=147) with median duration 25.3 months, ORR 48% with median duration 15.5 months, and overall median OS 11.5 months. Safety remained consistent with no new signals or new cases of differentiation syndrome reported.
Subgroup: patients with 1–2 prior regimens showed higher response rates and longer OS versus ≥3 prior regimens; 12 patients R/R to venetoclax had 33% CR/CRh and median OS 16.2 months.
Rigel Pharmaceuticals (Nasdaq: RIGL) will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT (5:00 a.m. ET).
The presentation will be delivered by Raul Rodriguez, president and CEO, and will be available via live webcast and as an archived recording on the company's Investor Relations website at www.rigel.com. Attendees are advised to connect to the website before the webcast to allow any necessary software downloads.
Rigel (Nasdaq: RIGL) reported Q3 2025 total revenue of $69.5M, including record net product sales of $64.1M (+65% YoY), and net income of $27.9M for the quarter. Year-to-date revenue was $224.5M. Cash, cash equivalents and short-term investments totaled $137.1M as of September 30, 2025.
The company completed dose escalation and began dose expansion in its Phase 1b R289 IRAK1/4 program and will present updated R289 data at ASH in December. Rigel raised 2025 revenue guidance to $285–$290M, including net product sales of $225–$230M, and expects positive net income for full-year 2025.
Rigel (Nasdaq: RIGL) will present updated clinical data at the 67th ASH Annual Meeting, Dec 6-9, 2025, in Orlando and virtually.
An oral presentation (Dec 7) will report updated Phase 1b safety and efficacy for R289 in relapsed/refractory lower‑risk MDS: dose range 250 mg QD to 500 mg BID, 33 patients enrolled (data cutoff Jul 15, 2025), median age 75, 61% high transfusion burden. At ≥500 mg QD evaluable transfusion‑dependent patients, 4/13 (31%) achieved durable RBC‑TI (>8 weeks); median time to RBC‑TI 2.2 months and median duration 24.3 weeks.
Four posters (Dec 6–8) report REZLIDHIA (olutasidenib) data in R/R mIDH1 AML, including late responses after stable disease, real‑world post‑venetoclax outcomes, hematologic improvement timing, and outcomes after prior intensive chemotherapy.
Rigel (Nasdaq: RIGL) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Senior management will host a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and provide a business update. Participants can join via domestic dial-in 877-407-3088 or international 201-389-0927, and the webcast (with slides) will be available on the company Investor Relations website at www.rigel.com.
The webcast will be archived for 90 days after the call. Rigel is a biotechnology company focused on therapies for hematologic disorders and cancer, headquartered in South San Francisco.
Rigel (Nasdaq: RIGL) announced the first patient has been enrolled in the dose expansion phase of its open-label Phase 1b study of R289 in transfusion dependent relapsed/refractory lower-risk myelodysplastic syndrome (MDS) on Oct 8, 2025. The dose expansion will randomize up to 40 patients to 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose (RP2D).
Enrollment in the dose escalation phase completed in July 2025. The company expects to share updated study data later in 2025. R289 has FDA Orphan Drug and Fast Track designations and remains investigational and not FDA approved.
Rigel Pharmaceuticals (Nasdaq: RIGL) on October 3, 2025 announced inducement equity awards under NASDAQ Listing Rule 5635(c)(4).
The company granted 41,138 stock options and 27,475 restricted stock units to 14 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the compensation committee under Rigel's Inducement Plan.
Rigel Pharmaceuticals (NASDAQ:RIGL), a biotechnology company focused on hematologic disorders and cancer, has announced its participation in four major investor conferences this September 2025.
The company's leadership, including CEO Raul Rodriguez and CFO Dean Schorno, will attend the Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and H.C. Wainwright Global Investment Conference. Company presentations are scheduled at Cantor (September 3, 8:35 a.m. ET) and H.C. Wainwright (September 9, 1:30 p.m. ET), with webcasts available through Rigel's investor relations website.
Rigel Pharmaceuticals (Nasdaq: RIGL) reported strong Q2 2025 financial results, with total revenue of $101.7 million, including net product sales of $58.9 million (76% YoY growth) and contract revenues of $42.7 million. The company generated $59.6 million in net income and increased its cash position to $108.4 million.
Key highlights include TAVALISSE sales of $40.1 million (52% YoY growth), GAVRETO sales of $11.8 million, and REZLIDHIA sales of $7.0 million (36% YoY growth). Rigel raised its 2025 guidance, projecting total revenue of $270-280 million, including net product sales of $210-220 million.
The company completed enrollment in Phase 1b study of R289 for R/R lower-risk MDS and expects to share updated data and initiate dose expansion later this year.
Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer therapies, will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss financial results and provide a business update. Investors can join via phone or access the webcast through Rigel's investor relations website, where it will remain available for replay for 90 days.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
